This story reports on carotid stenting as a possible alternative to endarterectomy. By framing it as stent vs. surgery, it assumes, however, that intervention needs to be done. While the evidence supports intervention for patients with symptoms of stroke, it is much less clear for patients who have carotid stenosis but no symptoms. By presenting the medical turf battle over ownership of this procedure, it provides some insight regarding the possibility of untoward enthusiasm for this intervention. The risk of stroke or death one year after stenting or surgery is presented as comparable at 10%. No comparison of risks was given for the use of blood-thinning or blood pressure drugs. In fact, non-surgical approaches (drugs or watchful waiting) received only a one-line mention in this story – almost as if they are out-moded ideas. Overall, the piece provided some context for following developments in this area of medicine.
Cost of stenting procedure put at $10 -15K; later mention of
Medicare restriction of coverage criteria.
Mentions 10% risk of stroke or death following stenting, though data source is not mentioned. Mentions side effects without
rates. Includes report from one patient of perceived benefit. Therefore incomplete.
See above – the piece does not provide
absolute rates for harms or side effects for various treatment options.
Does explain the weight placed on data from a randomized
clinical trial; careful read reveals that these data are not yet available. Not clear about the source of the data supporting
claim for comparable stroke and death rates for both stent and surgery. Does not make clear that the question about whether
or not to intervene really depends on whether the patient has stroke symptoms. If they have had a stroke or transient
ischemic attack, intervention is beneficial. The evidence for treating asymptomatic stenosis is much less clear.
Provides natural history. While harboring an element of disease mongering in terms of stroke concern it also
contains a flavor of over-enthusiasm by physicians to intervene; mentions the element of competition among specialties for
this piece of the medical care pie. The framing of the story implies that the falls and “unwell” feeling were caused by the
patient’s carotid blockage, which may not really be the case.
Good job pointing out medical turf battle over ownership of this procedure, and
industry sponsorship of symposium.
Mentions endarterectomy having
comparable outcome; single mention of medical treatment with no mention of outcome; no data for watchful waiting. Therefore,
incomplete.
Very clear presentation of FDA
approval of devices made by two manufacturers and that others are awaiting full approval.
Explains carotid stenting as
relatively new; piece later goes on to mention newer stenting systems with implanted filters
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like